scholarly journals Differences of Lower Urinary Tract Symptoms Degree In Benign Prostatic Hyperplasia Patients With and Without Diabetes Mellitus

Author(s):  
Jeannis Clarissa ◽  
Syah Mirsya Warli ◽  
Dhirajaya Dharma Kadar ◽  
Nurfida Khairina Arrasyid

Background. Benign Prostatic Hyperplasia (BPH) is a benign tumor that most often occurs in men. Many risk factors could cause BPH, one of which is diabetes mellitus (DM). Diabetes mellitus (DM) is a metabolic disease, characterized by hyperglycemia. Method. This study was conducted at the Urology Polyclinic of the Universitas  Sumatera Utara Hospital from August to September 2019. A total of 102 patients diagnosed with BPH were registered by cross-sectional study approach. Detailed medical history and physical examination were performed for all patients to diagnose BPH. While the diagnosis of DM was according to patient history or diabetic-medicine use. International Prostate Symptom Score (IPSS) were completed by all patients to obtain a LUTS degree. Result. From a total of 102 patients diagnosed with BPH there were 97 patients were selected. The mean age of patients was 70.43 ± 7.52 year (range 50-88 year) and the total IPSS score was 17.55 ± 6.55. DM patients were more likely to report severe LUTS and the symptom score evaluated with IPSS was significantly higher than in non non-DM group: 21.69 ± 5.41 vs 16.70 ± 6.41 (p=0.005). For the IPSS subscores, the DM group also show higher storage: 8.38 ± 4.57 vs 5.88 ± 3.72 (p = 0.02), voiding: 9.69 ± 2.47 vs 8.14 ± 3.21, (p= 0.039) and post micturition: 3.63 ± 1.26 vs 2.69 ± 1.744, (p= 0.045) symptoms significantly. Conclusion: Benign Prostatic Hyperplasia patients with DM manifested more severe lower urinary tract symptoms. Storage, voiding, post micturition, and urgency symptoms were also greater.

2021 ◽  
Vol 9 ◽  
pp. 205031212110473
Author(s):  
Tae Wook Kang ◽  
Jae Hung Jung ◽  
Dong Wook Kim ◽  
Kwang Ho Lee ◽  
Hyun Chul Chung

Purpose: To evaluate efficacy of 0.4 mg tamsulosin monotherapy in patients with benign prostatic hyperplasia with moderate-to-severe International Prostate Symptom Score. Material and methods: From May 2015 to May 2017, 102 patients were analyzed, retrospectively. The patients were classified into three groups according to the combination of medication (tamsulosin 0.4 mg vs tamsulosin 0.4 mg + solifenacin 5 mg vs tamsulosin 0.4 mg + mirabegron 50 mg). Baseline characteristics (e.g. age, body weight, height, and underlying medical disease) were collected. International Prostate Symptom Score, prostate specific antigen, prostate volume, peak urinary flow rate (Qmax), voided volume, and post-voided volume before after treatment were evaluated. Results: We classified and analyzed the patients into three groups depending on the medication. And there were no significant differences between all parameters among the groups. Voided volume at 3 months after treatment in each group was 170.54 ± 125.83, 121.55 ± 46.19, and 274.63 ± 132.30 ( p = 0.019). Differences of voiding symptom score and difference of post-voided volume among the groups before after treatment was 5.00 ± 5.42, 1.92 ± 3.92, and 0.11 ± 5.11 and 8.37 ± 34.32, 0.78 ± 14.86, −33.63 ± 28.58 ( p = 0.037, p = 0.007). Conclusion: We think tamsulosin monotherapy will be feasible as a first-line therapy for the patients with benign prostatic hyperplasia who has struggled with moderate-to-severe lower urinary tract symptoms.


Sign in / Sign up

Export Citation Format

Share Document